2002
DOI: 10.1021/jo0162890
|View full text |Cite
|
Sign up to set email alerts
|

Enantioselective Synthesis of Antiinfluenza Compound A-315675

Abstract: Drug discovery efforts at Abbott Laboratories have led to the identification of influenza neuraminidase inhibitor A-315675 (1) as a candidate for development as an antiinfluenza drug. A convergent, stereoselective synthesis of this highly functionalized pyrrolidine is reported that utilizes pyrrolinone 2 as the key intermediate. The C5, C6 stereochemistry was established through a diastereoselective condensation of chiral imine compound 3 with silyloxypyrrole 4 to give pyrrolinone 2. The stereochemical outcome… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
41
0

Year Published

2003
2003
2019
2019

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 101 publications
(43 citation statements)
references
References 19 publications
(21 reference statements)
0
41
0
Order By: Relevance
“…Two commercially available NA inhibitors, inhaled zanamivir and oral oseltamivir, have demonstrated clinical benefits in the prevention and treatment of seasonal influenza virus infections (1), whereas others are at some stage of development. Among the agents under development is a pyrrolidine-based compound from Abbott Laboratories (A-315675) that showed in vitro activity similar to that of zanamivir and oseltamivir when tested against influenza A (N1, N2, and N9 subtypes) and B viruses (5,9). In addition, A-315675 retains activity against influenza A/H1N1 viruses containing the oseltamivir resistance NA mutations H274Y and N294S, as well as NA enzymes of A/H3N2 viruses containing the oseltamivir resistance NA mutations E119V and N294S.…”
mentioning
confidence: 99%
“…Two commercially available NA inhibitors, inhaled zanamivir and oral oseltamivir, have demonstrated clinical benefits in the prevention and treatment of seasonal influenza virus infections (1), whereas others are at some stage of development. Among the agents under development is a pyrrolidine-based compound from Abbott Laboratories (A-315675) that showed in vitro activity similar to that of zanamivir and oseltamivir when tested against influenza A (N1, N2, and N9 subtypes) and B viruses (5,9). In addition, A-315675 retains activity against influenza A/H1N1 viruses containing the oseltamivir resistance NA mutations H274Y and N294S, as well as NA enzymes of A/H3N2 viruses containing the oseltamivir resistance NA mutations E119V and N294S.…”
mentioning
confidence: 99%
“…There are many nitrogen containing chemicals, ranging from simple structural compounds as pyridine to complicated compounds as pharmaceutical ingredients and their number is growing rapidly year by year 2 .Pyrrolidine based compounds have wide application in pharmaceutics ranging from use in the treatment of cancer 3 ,obesity 4 , fungal and viral infections 5 , HIV infection 6 and diabetes [7][8] .Piperazine nucleus is one of the most important heterocycle, exhibiting remarkable pharmacological activities as anthelminitis 9 , anti-HIV agent, antanginals 10 , urological 11 15 . Piperidine is also commonly used in sequencing of DNA 16 and in solid phase peptide synthesis 17 .…”
Section: Introductionmentioning
confidence: 99%
“…Two available NA inhibitors, zanamivir and oseltamivir have been found effective against seasonal infl uenza virus infection [6]. More inhibitors are in the stage of development like pyrrolidine-based compound from Abbott laboratories (A 315675) showing in vitro activity similar to that of zanamivir and oseltamivir against different strains (N1, N2, N9 subtypes) of infl uenza A viruses and B viruses [7,8].…”
Section: Introductionmentioning
confidence: 99%